European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Practice Guideline, Systematic Review
PubMed
38678762
DOI
10.1016/j.ejca.2024.114062
PII: S0959-8049(24)00718-4
Knihovny.cz E-resources
- Keywords
- Esophageal cancer, Gastric cancer, Metastasectomy, Metastasis, Oligometastasis, Stereotactic body radiotherapy,
- MeSH
- Delphi Technique MeSH
- Consensus MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Esophageal Neoplasms * therapy pathology diagnosis MeSH
- Stomach Neoplasms * therapy pathology diagnosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Systematic Review MeSH
- Geographicals
- Europe MeSH
INTRODUCTION: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). METHODS: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. RESULTS: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with ≤ 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. 18F-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI ≤ 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. DISCUSSION: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.
Danish Center of Particle Therapy Aarhus University Medical Center Aarhus University Aarhus Denmark
Department of Medical Oncology Catharina Cancer Institute Eindhoven the Netherlands
Department of Medical Oncology Elisabeth Tweesteden Ziekenhuis Tilburg the Netherlands
Department of Medical Oncology Hospital Universitario de Navarra Pamplona Spain
Department of Medical Oncology IRCM Inserm Université Montpellier ICM Montpellier France
Department of Medical Oncology KU Leuven Leuven University Leuven Belgium
Department of Medical Oncology Odense University Medical Center University of Odense Odense Denmark
Department of Medical Oncology Tallinn University Hospital Tallinn University Tallinn Estonia
Department of Medical Oncology University Hospital Leipzig University of Leipzig Leipzig Germany
Department of Medicine Johannes Gutenberg University Clinic University of Mainz Mainz Germany
Department of Oncology Aarhus University Hospital Aarhus University Aarhus Denmark
Department of Oncology and Radiotherapy Maria Skłodowska Curie Institute Warsaw Poland
Department of Oncology Cambridge University Hospitals Cambridge University Cambridge United Kingdom
Department of Radiation Oncology Amsterdam UMC location VUmc Amsterdam the Netherlands
Department of Radiation Oncology AZ Sint Maarten Mechelen Belgium
Department of Radiation Oncology Catharina Cancer Institute Eindhoven the Netherlands
Department of Radiation Oncology KU Leuven Leuven University Leuven Belgium
Department of Radiation Oncology Radboud University Medical Center Nijmegen the Netherlands
Department of Radiation Oncology Radiotherapiegroep Deventer the Netherlands
Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland
Department of Surgery Antoni van Leeuwenhoek Netherlands Cancer Institute Amsterdam the Netherlands
Department of Surgery Catharina Cancer Institute Eindhoven the Netherlands
Department of Surgery Fondazione Policlinico Universitario Agostino Gemelli Rome Italy
Department of Surgery Jagiellonian University Medical College Krakow Poland
Department of Surgery KU Leuven Leuven University Leuven Belgium
Department of Surgery Medical School National and Kapodistrian University of Athens Athens Greece
Department of Surgery Medical University of Vienna Vienna University Vienna Austria
Department of Surgery Siena University Hospital University of Siena Siena Italy
Department of Surgery University Hospital Cologne University of Cologne Cologne Germany
Department of Surgery University Hospital Geneva University of Geneva Geneva Switzerland
Department of Surgery University Medical Center Leiden University of Leiden Leiden the Netherlands
Department of Surgery University Medical Center Utrecht Utrecht University Utrecht the Netherlands
Department of Surgical Oncology Medical University of Lublin Lublin Poland
Department of Upper GI and General Surgery PanAsia Surgery Singapore
Trinity St James's Cancer Institute St James Hospital Trinity College Dublin Dublin Ireland
References provided by Crossref.org
